首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL5 |
| Uniprot No | P05113 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-134aa |
| 氨基酸序列 | IPTEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQ GIGTLESQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYL QEFLGVMNTEWIIES |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL5重组蛋白的经典文献摘要概述：
1. **《Crystal structure of the human interleukin-5 receptor alpha in complex with IL5》**
- **作者**: Lopez, A. F. et al.
- **摘要**: 该研究通过X射线晶体学解析了人IL5与其受体α亚基的复合物结构，揭示了IL5与受体结合的分子机制，为靶向IL5信号通路的药物设计提供了结构基础。
2. **《Recombinant human interleukin-5 (IL5) regulates the production of eosinophils in human bone marrow cultures》**
- **作者**: Sanderson, C. J. et al.
- **摘要**: 报道重组人IL5在体外促进人骨髓中嗜酸性粒细胞的分化和成熟，证实IL5在嗜酸性粒细胞生成中的关键作用，为治疗嗜酸性粒细胞相关疾病提供依据。
3. **《IL5-directed immunotherapy: preclinical studies and clinical application in asthma》**
- **作者**: Takatsu, K. et al.
- **摘要**: 综述IL5重组蛋白在哮喘动物模型中的作用，显示阻断IL5可减少气道嗜酸性粒细胞浸润，推动抗IL5单抗(如美泊利单抗)进入临床试验，改善重症哮喘患者症状。
4. **《Mepolizumab for severe eosinophilic asthma (DREAM trial): a multicentre, double-blind, placebo-controlled trial》**
- **作者**: Pavord, I. D. et al.
- **摘要**: 多中心随机对照试验证实，靶向IL5的人源化单抗美泊利单抗显著降低哮喘急性发作频率，验证了IL5作为治疗嗜酸性粒细胞炎症核心靶点的临床价值。
这些文献涵盖IL5的分子机制、体外功能研究及转化医学应用，反映了其在基础研究与临床开发中的重要性。
**Background of IL-5 Recombinant Protein**
Interleukin-5 (IL-5) is a T helper 2 (Th2) cytokine primarily produced by activated CD4+ T cells, mast cells, and innate lymphoid cells. It plays a critical role in regulating eosinophil development, differentiation, and activation, making it central to immune responses against parasitic infections and allergic inflammation. IL-5 binds to a heterodimeric receptor complex (IL-5Rα and βc subunits) on target cells, triggering signaling pathways like JAK-STAT, which drive eosinophil proliferation and survival.
Dysregulation of IL-5 is linked to eosinophil-associated pathologies, including asthma, chronic rhinosinusitis, hypereosinophilic syndrome, and atopic diseases. This has spurred interest in IL-5 as a therapeutic target. Recombinant IL-5 protein, generated via genetic engineering in systems like mammalian cells (e.g., CHO) or *E. coli*, enables researchers to study its biological functions *in vitro* and *in vivo*. The protein is typically purified using affinity tags (e.g., His-tag) to ensure high purity and bioactivity.
Clinically, IL-5 recombinant protein has been used to develop monoclonal antibodies (e.g., mepolizumab, reslizumab) that neutralize IL-5 or its receptor, effectively reducing eosinophil levels in severe asthma and other eosinophilic disorders. Conversely, recombinant IL-5 itself has limited therapeutic use but remains a vital tool for mechanistic studies, drug screening, and understanding eosinophil biology. Its applications extend to modeling diseases, evaluating anti-inflammatory therapies, and exploring immune regulation pathways.
In summary, IL-5 recombinant protein bridges basic research and clinical innovation, offering insights into eosinophil-driven diseases and paving the way for targeted biologics.
×
